Study design and procedures
migraine, headache
MIGRAINE
We enrolled participants in a randomized, double-blind, placebo-controlled, parallel trial at a single centre in Denmark (
Patients arrived between 08:00 a.m. and 12:00 p.m. on the experimental study days. Patients were in a supine-position during study-related procedures and assessments. Patients were not allowed to consume any medication within 24 h or four times the plasma half-life of the drug (whichever longest) on the experimental study days except for oral contraception. Furthermore, to remain eligible, participants could not have had a migraine attack during the preceding 48 h nor a headache during the preceding 24 h prior to administration of the experimental trigger.